



# MicroRNA-mediated Krüppel-like factor 4 upregulation induces alternatively activated macrophage-associated marker and chemokine transcription in 4,4'-methylene diphenyl diisocyanate exposed macrophages

Chen-Chung Lin, Brandon F. Law & Justin M. Hettick

**To cite this article:** Chen-Chung Lin, Brandon F. Law & Justin M. Hettick (2024) MicroRNA-mediated Krüppel-like factor 4 upregulation induces alternatively activated macrophage-associated marker and chemokine transcription in 4,4'-methylene diphenyl diisocyanate exposed macrophages, *Xenobiotica*, 54:9, 730-748, DOI: [10.1080/00498254.2024.2334329](https://doi.org/10.1080/00498254.2024.2334329)

**To link to this article:** <https://doi.org/10.1080/00498254.2024.2334329>



[View supplementary material](#)



Published online: 19 Apr 2024.



[Submit your article to this journal](#)



Article views: 215



[View related articles](#)



[View Crossmark data](#)

CrossMark

RESEARCH ARTICLE



# MicroRNA-mediated Krüppel-like factor 4 upregulation induces alternatively activated macrophage-associated marker and chemokine transcription in 4,4'-methylene diphenyl diisocyanate exposed macrophages

Chen-Chung Lin , Brandon F. Law  and Justin M. Hettick 

Allergy and Clinical Immunology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, WV, USA

## ABSTRACT

1. Occupational exposure to 4,4'-methylene diphenyl diisocyanate (MDI) is associated with occupational asthma (OA) development. Alveolar macrophage-induced recruitment of immune cells to the lung microenvironment plays an important role during asthma pathogenesis. Previous studies identified that MDI/MDI-glutathione (GSH)-exposure downregulates endogenous *hsa-miR-206-3p/hsa-miR-381-3p*. Our prior report shows that alternatively activated (M2) macrophage-associated markers/chemokines are induced by MDI/MDI-GSH-mediated Krüppel-Like Factor 4 (KLF4) upregulation in macrophages and stimulates immune cell chemotaxis. However, the underlying molecular mechanism(s) by which MDI/MDI-GSH upregulates KLF4 remain unclear.
2. Following MDI-GSH exposure, microRNA(miR)-inhibitors/mimics or plasmid transfection, endogenous *hsa-miR-206-3p/hsa-miR-381-3p*, KLF4, or M2 macrophage-associated markers (*CD206*, *TGM2*), and chemokines (*CCL17*, *CCL22*, *CCL24*) were measured by either RT-qPCR, western blot, or luciferase assay.
3. MDI-GSH exposure downregulates *hsa-miR-206-3p/hsa-miR-381-3p* by 1.46- to 9.75-fold whereas upregulates *KLF4* by 1.68- to 1.99-fold, respectively. *In silico* analysis predicts binding between *hsa-miR-206-3p/hsa-miR-381-3p* and *KLF4*. Gain- and loss-of-function, luciferase reporter assays and RNA-induced silencing complex-immunoprecipitation (RISC-IP) studies confirm the posttranscriptional regulatory roles of *hsa-miR-206-3p/hsa-miR-381-3p* and *KLF4* in macrophages. Furthermore, *hsa-miR-206-3p/hsa-miR-381-3p* regulate the expression of M2 macrophage-associated markers and chemokines via *KLF4*.
4. In conclusion, *hsa-miR-206-3p/hsa-miR-381-3p* play a major role in regulation of MDI/MDI-GSH-induced M2 macrophage-associated markers and chemokines by targeting the *KLF4* transcript, and *KLF4*-mediated regulation in macrophages.

## ARTICLE HISTORY

Received 20 February

2024

Revised 19 March 2024

Accepted 20 March 2024

## KEYWORDS

Occupational asthma (OA); diisocyanates (dNCOs); 4,4'-methylene diphenyl diisocyanate (MDI); microRNAs (miRs); Krüppel-like factor 4 (KLF4)

## Introduction

Diisocyanates (dNCOs) are highly reactive chemicals used for polyurethane production in many applications (Allport et al. 2003). 4,4'-methylene diphenyl diisocyanate (MDI) is the world's most produced and utilised dNCO with evolving industrial applications, and also in consumer products (e.g. spray-on truck bed liners, spray foam insulation, car instrument panels, self-expanding memory foam mattresses, three-dimensional printing, etc.) (USEPA 2011; Jones et al. 2017). As such, both global production and the market for MDI are predicted to continue to grow (Statista 2022). Workplace exposure to MDI can lead to development of occupational asthma (OA) and even death in exposed workers (Bernstein et al. 1993; NIOSH 1994a, 1994b; Redlich and Karol 2002; Lofgren et al. 2003; NIOSH 2004; Jan et al. 2008; Engfeldt et al. 2013; Wisnewski et al. 2022); however, the detailed molecular mechanism(s) that participated in the pathogenesis of MDI-OA remain unclear.

Recruitment of immune cells such as eosinophils and T-cells into the lung microenvironment following irritation or allergen exposure in the airways, as well as the interactions between infiltrated immune cells and the airway cells in the lung microenvironment play critical roles during asthma pathogenesis (Barnes 2008; Holgate 2008; Boonpiyathad et al. 2019). Alveolar macrophages have been implicated in the development of asthma (Fricker and Gibson 2017), and alternatively activated (M2) macrophage populations have been found to be elevated in the airways of asthmatic patients (Girodet et al. 2016). By using an MDI-OA animal model, Wisnewski and colleagues showed that many immune cell types, including macrophages, T-cells, and eosinophils can be recruited into the lung microenvironment with induced alternatively activated (M2) macrophage-associated gene signatures after MDI/MDI-GSH exposure (Wisnewski et al. 2015; 2020). Our previous report showed that *in vivo* MDI exposure and *in vitro* MDI-glutathione (GSH) conjugate exposure upregulates some M2 macrophage-associated markers as well as

**CONTACT** Chen-Chung Lin   Allergy and Clinical Immunology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, 1095 Willowdale Rd, MS L4020, Morgantown, WV 26505, USA.

 Supplemental data for this article can be accessed online at <https://doi.org/10.1080/00498254.2024.2334329>.

This article has been corrected with minor changes. These changes do not impact the academic content of the article.

This work was authored as part of the Contributor's official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.

chemokine expression through induction of M2 macrophage-associated transcriptional factor, Krüppel-Like Factor 4 (KLF4) (Lin et al. 2023). KLF4 belongs to the zinc-finger transcription factor family and is expressed in a wide variety of mammalian tissues, where it contributes to regulation of proliferation, differentiation, development, tissue homeostasis and apoptosis (Ghaleb and Yang 2017). In macrophages, KLF4 regulates macrophage differentiation and M2 macrophage polarisation (Park et al. 2016); however, the detailed molecular mechanism(s) by which MDI/MDI-GSH exposure induces KLF4 is currently unclear.

MicroRNAs (miRs) are single-stranded, noncoding RNA molecules ranging from 19 to 24 nucleotides in length with the capacity to inhibit protein translation and promote mRNA degradation by imperfectly binding to their target RNA transcripts. Through posttranscriptional regulation of their target genes, miRs are involved in regulating various cellular processes such as the cell cycle, proliferation, apoptosis, and differentiation in many different cell types (Bartel 2018). Additionally, endogenous miR expression profile changes have been implicated in the pathogenesis of several lung diseases including asthma (Sittka and Schmeck 2013; Weidner et al. 2020). Other reports have determined that KLF4 can be post-transcriptionally regulated by miRs in both normal and disease conditions (Ghaleb and Yang 2017; Li et al. 2023). Furthermore, KLF4 has been previously shown to be regulated by *hsa-miR-206-3p* in many different cell types (Parasramka et al. 2012; Ren et al. 2014; Wang et al. 2021). In asthmatic children, there is a negative correlation between KLF4 and *hsa-miR-206-3p* levels in peripheral blood mononuclear cells (PBMCs) (Qinglei et al. 2015). The murine *Klf4* transcript is *in silico* predicted to be co-targeted by murine miRs *mmu-miR-206-3p* and *mmu-miR-381-3p* (Lin et al. 2019). Our previous reports determined that exposure to MDI-GSH conjugate downregulates endogenous levels of *hsa-miR-206-3p* and *hsa-miR-381-3p* in macrophages (Lin et al. 2020, 2021). Therefore, we hypothesise that MDI-mediated downregulation of *hsa-miR-206-3p* and/or *hsa-miR-381-3p* may participate in the regulation of KLF4 expression following MDI exposure.

The current report focuses on characterising whether MDI-mediated *hsa-miR-206-3p* and/or *hsa-miR-381-3p* downregulation may participate in the regulation of endogenous KLF4 and KLF4-mediated regulation of downstream M2 macrophage-associated markers and chemokine responses *in vitro* using human THP-1 macrophages. *In vitro* MDI-GSH conjugate exposure exhibits downregulation of endogenous *hsa-miR-206-3p* and *hsa-miR-381-3p* and subsequent upregulation of KLF4 signalling-mediated induction of M2 macrophage-associated markers and chemokines. This report provides a putative miR-regulated mechanism to describe how KLF4 and KLF4-mediated M2 macrophage-associated markers and chemokines are upregulated following MDI/MDI-GSH exposure in macrophages.

## Materials and methods

### Chemicals and reagents

High-performance liquid chromatography (HPLC) grade acetone, 3 Å molecular sieve (4-8 mesh), phosphate buffered

saline (PBS), Tris Buffered Saline (TBS), Tween-20, Dimethyl sulfoxide (DMSO), 4,4'-methylene diphenyl diisocyanate (MDI, 98% purity), phorbol 12-myristate 13-acetate (PMA), and reduced-glutathione (GSH) were acquired from MilliporeSigma (St. Louis, MO). Roswell Park Memorial Institute (RPMI)-1640 culture medium, radioimmunoprecipitation assay (RIPA) buffer, Penicillin-Streptomycin-Glutamine (PSG; 100×), and Foetal Bovine Serum (FBS) were purchased from ThermoFisher Scientific (Waltham, MA). Kenpaullone was purchased from Santa Cruz Biotechnology (Dallas, TX). Dry acetone was prepared by incubating 10 ml HPLC grade acetone on 3 Å molecular sieve for a minimum of 24 h to adsorb water.

### Cell culture and differentiation

THP-1 (ATCC® TIB-202™) was obtained from American Type Culture Collection (ATCC; Manassas, VA) and maintained at 0.5–1 × 10<sup>6</sup>/ml in RPMI-1640 media supplemented with 10% FBS, and 1 × PSG (Complete RPMI media) at 37 °C in a humidified atmosphere with 5% CO<sub>2</sub> as previously described (Lin et al. 2023). THP-1 cells (2 × 10<sup>6</sup> cells) were differentiated into macrophages by addition of 10 ng/mL PMA in 10 cm culture dishes for 72 h. Differentiation was further enhanced by removal of the PMA-containing media, washing twice with PBS and then incubating the cells in fresh complete media for another 72 h. PMA differentiation at 10 ng/mL to THP-1 monocytes has been shown to enhance responsiveness to polarising stimuli (Maeß et al. 2014; Baxter et al. 2020). All *in vitro* cell experiments described in this study used enhanced, differentiated THP-1 macrophages.

### MDI-GSH conjugation reactions

MDI-GSH conjugates were prepared as previously reported (Lin et al. 2020, 2023). Briefly, 10 mM GSH solution was prepared in 200 mM sodium phosphate buffer (pH= 7.4). Fifty µL of freshly prepared stock solutions of 10% MDI (w/v) in dry acetone were added to 25 ml of GSH solution dropwise with stirring, to achieve an MDI concentration of approximately 800 µM. Upon addition of MDI to GSH solution, reactions were incubated at 25 °C with end-over-end mixing for 1 h. The reaction mixture was then centrifuged at 10,000 × g and filtered with a 0.2 µm syringe filter. Reaction products containing MDI-GSH conjugate were immediately added into either differentiated THP-1 macrophages, or THP-1 macrophages with kenpaullone treatment at 10 µM of MDI-GSH.

### Plasmid construction

pMIR-REPORT firefly luciferase vector was obtained from ThermoFisher Scientific (Waltham, MA). pRL-TK Renilla luciferase reporter was obtained from Promega (Madison, WI). Expression plasmids pCMV6-Entry-KLF4 (Origene ID: RC206691) and pCMV6-Entry (ID: PS100001) were obtained from Origene (Rockville, MD). To construct a wildtype (WT) *KLF4* 3'UTR luciferase translational reporter, a 0.9-kb cDNA fragment representing the 3'UTR of human *KLF4* (NM\_004235.6) was generated by PCR using a *Mlu*I restriction site containing forward primer

(ccgacgcgtATCCCAGACAGTGGATATGACCCA) and a *Pmel* restriction site containing reverse primer (ccgtttaaacTTCAGATA-AAAATTATAGGTTTA) on THP-1 cell cDNA. The PCR-amplified *KLF4*-3'UTR cDNA fragment was treated with *Mlu*I and *Pmel*. This fragment was inserted into pMIR-REPORT vector that was prepared by sequential enzyme treatments with *Mlu*I, *Pmel*, and calf intestinal alkaline phosphatase (CIP).

### Transient transfection and translational reporter assays

For *KLF4* overexpression,  $1 \times 10^6$  enhanced-differentiated THP-1 macrophages were reverse transfected with  $2.5 \mu\text{g}$  of either pCMV6-Entry-*KLF4* expression plasmid or pCMV6-Entry empty vector using Mirus *TransIT*-2020 transfection reagent in a 6-well plate for 48h. After 48h, total RNA was isolated using *mirVana*<sup>TM</sup> miR Isolation Kit (ThermoFisher Scientific) according to manufacturer's instruction for RT-qPCR expression analyses. For miR functional analyses, the following *mirVana*<sup>TM</sup> miRNA inhibitors (MH) and, miR-mimics (MC) were obtained from ThermoFisher Scientific and diluted to  $20 \mu\text{M}$  in nuclease-free water: *hsa-miR-206-3p* (MH10409, MC10409), *hsa-miR-381-3p* (MH10242, MC10242) MH-negative control #1 (4464076), and MC-negative control #1 (4464058). Cells were subjected to reverse transfection and 24h later, forward transfection was performed as previously described (Lin et al. 2011). Twenty-four hours after the start of the forward transfection, cell extracts were prepared for RT-qPCR expression analyses. Translational luciferase reporter assays were performed following just one transfection, at 24h after the start of the reverse transfection. MiR-inhibitors or -mimics were co-transfected with *KLF4*-3'UTR luciferase translational reporter plasmid, including the pRL-TK control, and Dual-Luciferase Reporter Assays (Promega) were performed as previously described (Lin et al. 2011).

### Expression analyses

For RT-qPCR assays, total RNA from THP-1 macrophages was extracted using *mirVana*<sup>TM</sup> miR Isolation Kit (ThermoFisher Scientific) according to manufacturer's instructions. PCR reactions were performed on an ABI 7500 Real-Time PCR System from ThermoFisher Scientific (Waltham, MA). The mRNA and miR levels were analysed as previously described (Lin et al. 2019; 2020). Reactions were normalised to human beta-2 microglobulin (*B2M*) for mRNA analysis and *U6* snRNA for miR analysis. Gene/miR expression assays used in this study were acquired from ThermoFisher Scientific and include: human *KLF4* (Cat#4331182; Assay ID: Hs00358836\_m1), *TGM2* (Hs01096681\_m1), *CD206* (Hs00267207\_m1), *CCL17* (Hs00171074\_m1), *CCL22* (Hs01574247\_m1), *CCL24* (Hs00171082\_m1), and *B2M* (Hs00187842\_m1), *hsa-miR-206-3p* (Cat# 4427975; Assay ID No. 000510; *hsa/Homo sapiens*), *hsa-miR-381-3p* (No. 000571), and *U6* snRNA (No. 001973).

### Immunoblot and antibodies

Cell extracts for immunoblot were prepared in RIPA buffer as previously described (Lin et al. 2020, 2023). Following

electrophoresis, proteins were transferred onto nitrocellulose membranes and probed with diluted antibodies in TBST containing 1% BSA. Specific antibody against human *KLF4* (Cat#AB4138) was obtained from MilliporeSigma (Burlington, MA). Antibody against  $\beta$ -actin (Cat#sc-47778) was obtained from Santa Cruz Biotechnology (Dallas, TX). Bound antibodies were detected using Pierce ECL Western Blotting Substrate (ThermoFisher Scientific).

### Validation of miR target by argonaute (AGO) immunoprecipitation

Immunoprecipitation (IP) of the miR-containing RNA inducing silencing complex (miR/RISC) and miR targeting mRNAs was performed using the miRNA target IP kit (Active Motif, Carlsbad, CA) as previously described (Lin et al. 2020). Briefly, enhanced-differentiated THP-1 macrophages were trypsinized and seeded at  $8 \times 10^6$  cells in 10cm dishes. The cells were transfected with  $25 \text{ nM}$  of either miR-mimic-206-3p or miR-mimic-381-3p or miR-mimic negative control #1 for 24h. Two 10cm dishes of cells using an equal number of  $1.6 \times 10^7$  cells were taken for the IP reaction. After cell lysis, the lysates were divided into two equal aliquots. Each lysate aliquot underwent IP by using either a pan-AGO antibody to precipitate the RISC containing AGOs/miRs/mRNAs or an isotype IgG antibody control. The precipitated complex was collected, and the RNA was purified from the RISC complex using *mirVana*<sup>TM</sup> miR Isolation Kit (ThermoFisher Scientific). The RNA was converted to cDNA using the High-Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific) and TaqMan qPCR assays of human *KLF4*, *TGM2* and *CCL22* was used for RT-qPCR. The data was analysed by comparing the cells transfected with miR-mimics or non-target miR-mimic-control oligonucleotide and the fold enrichment of either *KLF4*, *TGM2* or *CCL22* was calculated from the anti-panAGO and the IgG isotype antibody IP preparations as described by the manufacturer.

### In silico analysis of predicted interactions between *KLF4*, *CD206*, *TGM2*, *CCL17*, *CCL22*, *CCL24* transcripts and *hsa-miR-206-3p/hsa-miR-381-3p*

Potential interactions between the 3'UTRs of human *KLF4*, *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcripts and *hsa-miR-206-3p/hsa-miR-381-3p* were first examined using the online *in silico* tool, TargetScanHuman v8.0 ([http://www.targetscan.org/vert\\_80/](http://www.targetscan.org/vert_80/)) (Agarwal et al. 2015; McGahey et al. 2019). Candidate miR-mRNA interactions were further examined with several *in silico* algorithms including miRanda (Enright et al. 2003), PicTar (Krek et al. 2005), PITA (Kertesz et al. 2007), and RNA22 (Miranda et al. 2006) using the web-based tool miRsystem (<http://mirsystem.cgm.ntu.edu.tw/>) (Lu et al. 2012). Furthermore, two online databases containing the most recent experimentally supported miR-gene interactions were queried to verify candidate miR binding to candidate mRNAs as followed: DIANA-TarBase v.8 (<https://dianalab.e-ce.uth.gr/html/diana/web/index.php?r=tarbasev8>) (Karagkouni et al. 2018) and miRTarBase (<https://mirtarbase>).

[cuhk.edu.cn/~miRTarBase/miRTarBase\\_2022/php/index.php](http://cuhk.edu.cn/~miRTarBase/miRTarBase_2022/php/index.php)  
(Huang et al. 2020).

### Statistical analysis

Data were analysed using either the unpaired *t*-test (two-tailed) when comparing two groups, or one-way analysis of variance followed by Tukey's multiple comparison *ad hoc* post-test when comparing multiple groups. Statistical analyses were performed in GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA, USA.). Differences were considered significant when the analysis yielded  $p < 0.05$ .

## Results

### **Endogenous hsa-miR-206-3p/hsa-miR-381-3p are downregulated and KLF4 is upregulated in MDI-GSH conjugate treated macrophages**

Our previous reports demonstrated that exposure to MDI/MDI-GSH conjugates downregulate endogenous *hsa-miR-206-3p* and *hsa-miR-381-3p* levels (Lin et al. 2020, 2021) and upregulates endogenous *KLF4* levels (Lin et al. 2023) in THP-1 macrophages. To further investigate whether MDI-GSH conjugate exposure simultaneously regulates endogenous *KLF4* as well as either *hsa-miR-206-3p* or *hsa-miR-381-3p* expressions, differentiated-enhanced THP-1 macrophages were treated with MDI-GSH conjugates at concentrations of 0, 1, and 10  $\mu$ M for 24 h. In agreement with our previous observations, the endogenous *hsa-miR-206-3p* was significantly downregulated 1.46-fold to 2.63-fold (Figure 1A) and endogenous *hsa-miR-381-3p* was significantly downregulated 1.47-fold to 9.75-fold (Figure 1B) after MDI-GSH conjugate exposure in THP-1 macrophages. Endogenous *KLF4* mRNA was significantly upregulated 1.68-fold to 1.99-fold (Figure 1C) and the endogenous *KLF4* protein was also upregulated after MDI-GSH conjugate exposure in THP-1 macrophages (Figure 1D). These results confirm that exposure to MDI in the form of MDI-GSH conjugates can simultaneously upregulate the endogenous *KLF4* and decrease endogenous *hsa-miR-206-3p* and *hsa-miR-381-3p* levels in macrophages.


### ***KLF4*-mediated signalling is partially involved in the regulation of MDI-GSH conjugate-mediated induction of M2 macrophage-associated markers and chemokines in differentiated THP-1 macrophages**

Previous studies in our laboratory demonstrated that exposure to MDI/MDI-GSH conjugates may induce M2 macrophage-associated markers and chemokines including *Cd206/CD206*, *Tgm2/TGM2*, *Ccl17/CCL17*, *Ccl22/CCL22* and *CCL24* partially through induction of endogenous *Klf4/KLF4* expression in bronchial alveolar lavage cells (BALCs)/alveolar macrophages (Lin et al. 2023). We utilised specific siRNAs that were designed to target endogenous mature *KLF4* mRNA transcripts within the cytosol to degrade *KLF4* transcripts and therefore knockdown *KLF4* protein levels in

macrophages. The siRNA-mediated knockdown of *KLF4* protein revealed that *KLF4* plays a role in regulating M2 macrophage-associated markers and chemokines (Lin et al. 2023). One of the major aims for the current study is to investigate whether miRs can target *KLF4* and therefore regulate *KLF4* protein expression, however, miRs and siRNAs employ similar RISC-mediated gene inhibition mechanisms to downregulate target gene expression (Lam et al. 2015). To avoid possible competition between *KLF4* siRNAs and *hsa-miR-206-3p/hsa-miR-381-3p* for RISCs in macrophages, we utilised chemical inhibitors of *KLF4* to determine whether *KLF4*-mediated transcriptional control after MDI-exposure participates in the regulation of M2 macrophage-associated markers and chemokines including *CD206*, *TGM2*, *CCL17*, *CCL22* and *CCL24*. We treated THP-1 macrophages with kenpaullone, a chemical inhibitor of *KLF4* (Lyssiotis et al. 2009; Tien et al. 2015; Montecillo-Aguado et al. 2021), to inhibit the endogenous *KLF4* function in macrophages with or without MDI-GSH conjugate exposure (Figure 2). Compared to the vehicle control treated THP-1 macrophages, treatment of 1  $\mu$ M kenpaullone significantly downregulated endogenous *KLF4*, *CD206*, *CCL17* and *CCL22* transcripts by 15.9-, 2.10-, 13.3-, and 2.28-fold (Figure 2A, B, D, and E), respectively, whereas other M2 macrophage-associated markers and chemokines including *TGM2* and *CCL24* transcripts were not significantly changed (Figure 2C, F). In agreement with previous findings, exposure to 10  $\mu$ M of MDI-GSH conjugate upregulated endogenous *KLF4*, *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcript expression by 3.06-, 1.57-, 1.91-, 2.87-, 1.78-, and 2.56-fold, respectively (Figure 2A–F). Furthermore, the induction of endogenous *KLF4*, *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcripts by MDI-GSH conjugate (10  $\mu$ M) exposure were attenuated by treatment with 1  $\mu$ M of kenpaullone (Figure 2A–F). These results indicate that MDI-exposure mediated activation of *KLF4* and *KLF4*-mediated downstream signalling plays a role in regulation of the MDI-mediated induction of M2 macrophage-associated marker and chemokine transcript expression in macrophages.

### ***Inhibition of either hsa-miR-206-3p or hsa-miR-381-3p upregulates KLF4 and M2 macrophage-associated markers CD206, TGM2, CCL17, CCL22 and CCL24 in macrophages***

We previously reported that *KLF4* mediates the induction of M2 macrophage-associated markers *CD206* and *TGM2* as well as chemokines *CCL17*, *CCL22*, and *CCL24* after MDI/MDI-GSH exposure in macrophages (Lin et al. 2023) and the induction of *KLF4* is associated with downregulation of *hsa-miR-206-3p* and *hsa-miR-381-3p* after MDI-GSH conjugate exposure in macrophages as shown in Figure 1. Furthermore, the murine *Klf4* transcript is *in silico* predicted to be coregulated by murine miRs *mmu-miR-206-3p/mmu-miR-381-3p* (Lin et al. 2019). These observations led us to hypothesise that endogenous *hsa-miR-206-3p* or *hsa-miR-381-3p* may contribute to M2 macrophage-associated marker *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* regulation in macrophages through




**Figure 1.** MDI-GSH conjugates downregulate endogenous *hsa-miR-206-3p* and *hsa-miR-381-3p* and upregulate endogenous *KLF4* in differentiated THP-1 macrophages. Total RNA was isolated from MDI-GSH treated differentiated THP-1 macrophages at indicated concentration for 24 h by *miRVana™* miR isolation kit, reverse transcribed, and subjected to TaqMan RT-qPCR assays. Endogenous levels of (A) *hsa-miR-206-3p* and (B) *hsa-miR-381-3p* as well as (C) *KLF4* transcripts were determined at 24 h after MDI-GSH conjugate treatment ( $N=3$ ; bars, SEM). (D) Endogenous *KLF4* protein was analysed by immunoblot.  $\beta$ -actin served as a loading control. MDI: 4,4'-methylene diphenyl diisocyanate. GSH: Glutathione (\* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.001$ ).

*hsa-miR-206-3p/hsa-miR-381-3p*-mediated posttranscriptional regulation of *KLF4*. To investigate the role of *hsa-miR-206-3p* and *hsa-miR-381-3p* in regulation of endogenous *KLF4* and M2 macrophage-associated marker transcripts, we utilised loss- or gain-of-function studies by transfecting macrophages with either miR-inhibitors or miR-mimics of *hsa-miR-206-3p* and *hsa-miR-381-3p*. Loss-of-function studies were performed by transfecting miR-inhibitors of either *hsa-miR-206-3p* or *hsa-miR-381-3p* into differentiated THP-1 macrophages to mimic the effects observed as MDI-GSH conjugate treatment downregulates endogenous *hsa-miR-206-3p* and *hsa-miR-381-3p* levels in macrophages (Figure 1A,B). In agreement with the finding that *KLF4* transcripts are upregulated after MDI-GSH conjugate exposure (Figure 1C), transfection of miR-inhibitor-206-3p upregulates endogenous *KLF4* by 3.59-fold and transfection of miR-inhibitor-381-3p upregulates endogenous *KLF4* by 2.16-fold (Figure 3A). Furthermore, transfection of miR-inhibitor-206-3p upregulates endogenous

M2 markers *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcripts by 1.56-, 1.42-, 3.22-, 2.58-, and 2.47-fold, respectively (Figure 3B-F). Similarly, transfection of miR-inhibitor-381-3p upregulates endogenous M2 markers *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcripts by 3.48-, 2.02-, 2.48-, 2.56-, and 3.43-fold, respectively (Figure 3B-F). These results indicate that both the endogenous *KLF4* transcript and M2 macrophage-associated marker mRNAs may be regulated by either endogenous *hsa-miR-206-3p* or *hsa-miR-381-3p* in macrophages.

**Mimics of either hsa-miR-206-3p or hsa-miR-381-3p downregulate KLF4 and M2 macrophage-associated markers CD206, TGM2, CCL17, CCL22 and CCL24 in macrophages**


Using a gain-of-function approach by transfection of miR-mimics, we further explored the regulatory function of



**Figure 2.** KLF4 inhibition attenuate MDI-GSH mediated induction of M2 macrophage-associated marker and chemokine expression in differentiated THP-1 macrophages. The differentiated THP-1 macrophages were treated either with 1 μM of Kenpauallone or vehicle for 24 h followed by treatment with or without 10 μM MDI-GSH conjugates for 24 h. Total RNA were isolated from THP-1 macrophages with indicated treatment by *miRVana*™ miR isolation kit, reverse transcribed, and subjected to TaqMan stem-loop RT-qPCR. The endogenous M2 macrophage-associated transcription factor (A) *KLF4*, markers (B) *CD206*, (C) *TGM2*, (D) *CCL17*, (E) *CCL22*, and (F) *CCL24* mRNA levels were determined in total RNA isolated from THP-1 macrophages ( $N=3$ ; bars, SEM). Vehicle (Ctl): RPMI-1640 media containing 10% FBS and 0.01% DMSO. MDI: 4,4'-methylene diphenyl diisocyanate. GSH: Glutathione. (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  when compared to vehicle treated macrophages; # $p < 0.05$ , ### $p < 0.001$ , when compared to macrophages treated with vehicle followed by 10 μM MDI-GSH conjugate exposure).

*hsa-miR-206-3p* and *hsa-miR-381-3p* to inhibit the endogenous levels of *KLF4* and M2 macrophage-associated marker transcripts. Transfection of miR-mimic-206-3p downregulated endogenous *KLF4* by 3.09-fold and transfection of miR-mimic-381-3p downregulated endogenous *KLF4* by 6.45-fold (Figure 4A). In addition, transfection of miR-mimic-206-3p downregulated endogenous M2 macrophage-associated markers *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcripts by 8.07-, 2.24-, 1.67-, 2.54-, and 2.95-fold, respectively, whereas transfection of miR-mimic-381-3p downregulated endogenous *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcripts by 4.30-, 2.69-, 3.14-, 2.48-, and 2.22-fold, respectively (Figure 4B-F). Given that miR-inhibitors of both

*hsa-miR-206-3p* and *hsa-miR-381-3p* upregulate *KLF4* expression (Figure 3A), and the miR-mimics of both *hsa-miR-206-3p* and *hsa-miR-381-3p* downregulate endogenous *KLF4* (Figure 4A), these results suggest that the *KLF4* transcript may be post-transcriptionally regulated by *hsa-miR-206-3p/hsa-miR-381-3p* in macrophages. Furthermore, the endogenous M2 macrophage-associated markers *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcripts are regulated by *hsa-miR-206-3p/hsa-miR-381-3p* in macrophages (Figure 3B-F; Figure 4B-F). Together with the observation that *hsa-miR-206-3p/hsa-miR-381-3p* downregulate *KLF4*, these data indicate that the elevation of M2 macrophage-associated markers *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcripts in response to MDI-GSH



**Figure 3.** Transfection of miR-inhibitors of *hsa-miR-206-3p* and *hsa-miR-381-3p* induce endogenous M2 macrophage-associated markers and chemokines in differentiated THP-1 macrophages. THP-1 macrophages were transfected with 25nM of either miR-inhibitor-206-3p, miR-inhibitor-381-3p or nontargeting miR-inhibitor control (miR-inhibitor-Ctl) for 48 h. Total RNA were isolated from the indicated miR-inhibitor transfected THP-1 macrophages by *miRVana*<sup>TM</sup> miR isolation kit, reverse transcribed, and subjected to TaqMan RT-qPCR. Endogenous mRNA expressions of (A), *KLF4*, (B) *CD206* (C) *TGM2*, (D) *CCL17*, (E) *CCL22*, and (F) *CCL24* were determined by RT-qPCR ( $N=3$ ; bars, SEM). (\* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.001$ ).


conjugate exposure is likely to be regulated by *hsa-miR-206-3p/hsa-miR-381-3p*-mediated *KLF4* transcriptional activation.

#### Human *KLF4* transcript as a potential target for either *hsa-miR-206-3p* or *hsa-miR-381-3p*

Previous study in our laboratory showed that the murine *Klf4* transcript is *in silico* predicted to be regulated by either murine miRs *mmu-miR-206-3p* or *mmu-miR-381-3p* (Lin et al. 2019). Given that murine *Klf4* transcripts are highly conserved in humans and the murine miRs *mmu-miR-206-3p* and *mmu-miR-381-3p* are identical to their human counterparts *hsa-miR-206-3p* and *hsa-miR-381-3p*, we further examined the potential binding of *hsa-miR-206-3p* and *hsa-miR-381-3p* with the human *KLF4* transcript (NM\_004235.5) using the *in silico* miR-target prediction tool miRDB (Wong and Wang 2015) and TargetScanHuman 8.0 (Agarwal et al. 2015; McGahey et al.

2019). *In silico* analysis identified one putative *hsa-miR-206-3p* binding site and two *hsa-miR-381-3p* predicted binding sites located in the 3'UTR of the *KLF4* transcript (Figure 5A).

To investigate whether *hsa-miR-206-3p* and/or *hsa-miR-381-3p* can regulate endogenous *KLF4* expression in differentiated THP-1 macrophages, we performed gain- and loss-of-function studies by transfecting either miR-mimics or miR-inhibitors of *hsa-miR-206-3p* and *hsa-miR-381-3p* into differentiated/enhanced THP-1 macrophages. Independent transfections of either miR-mimic-206-3p or miR-mimic-381-3p downregulated endogenous *KLF4* protein (Figure 5B) and RNA (Figure 5C) compared to the miR-mimic control. Because MDI-GSH conjugate treatment decreased endogenous *hsa-miR-206-3p* and *hsa-miR-381-3p* levels in differentiated THP-1 macrophages (Figure 1A,B), we performed a loss-of-function study by transfecting differentiated THP-1 macrophages with miR-inhibitor-206-3p, miR-inhibitor-381-3p



**Figure 4.** Transfection of miR-mimics of *hsa-miR-206-3p* and *hsa-miR-381-3p* decrease endogenous M2 macrophage-associated markers and chemokines in differentiated THP-1 macrophages. THP-1 macrophages were transfected with 25 nM of either miR-mimic-206-3p, miR-mimic-381-3p or nontargeting miR-mimic control (miR-mimic-Ctl) for 48 h. Total RNA was isolated from the indicated miR-mimics transfected THP-1 macrophages by *miRVana*<sup>TM</sup> miR isolation kit, reverse transcribed, and subjected to TaqMan RT-qPCR. Endogenous mRNA expressions of (A), *KLF4*, (B) *CD206* (C) *TGM2*, (D) *CCL17*, (E) *CCL22*, and (F) *CCL24* were determined by RT-qPCR ( $N=3$ ; bars, SEM). (\* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.001$ ).

and a non-targeting miR-inhibitor control to investigate whether the endogenous *KLF4* level would be affected by either *hsa-miR-206-3p* or *hsa-miR-381-3p*. Consistent with *KLF4* as a target of either *hsa-miR-206-3p* or *hsa-miR-381-3p*, independent transfection of either miR-inhibitor-206-3p or miR-inhibitor-381-3p increased endogenous *KLF4* protein level (Figure 5D), as well as increased endogenous *KLF4* mRNA level (Figure 5E). These data further suggest that *KLF4* transcript may be a potential direct target of either *hsa-miR-206-3p* or *hsa-miR-381-3p* in differentiated macrophages.

#### Verification of *KLF4* transcript as a direct target of either *hsa-miR-206-3p* or *hsa-miR-381-3p* in differentiated THP-1 macrophages

A potential target gene that is regulated by miRs may be either directly regulated by binding of a particular miR or

through other miR-regulated pathways (e.g. transcriptional, or posttranscriptional regulation) (Tsang et al. 2007; Inui et al. 2010). The miR-mediated translational repression or mRNA transcript degradation of miR-targeted mRNAs is regulated through the binding of a miR-containing RISC which contains argonaute proteins (AGOs) and other proteins including RNases or translational repressors to the 3'UTR of the target mRNAs (Gregory et al. 2005). To determine if *KLF4* transcripts are directly regulated by either *hsa-miR-206-3p* or *hsa-miR-381-3p*, we first confirmed the binding of either *hsa-miR-206-3p* or *hsa-miR-381-3p* to *KLF4* transcript by performing a pan-argonaute (AGO) antibody pulldown method to precipitate the RISCs which contain AGOs/miRs/mRNAs (RISC-IP), and followed by confirming the roles of *hsa-miR-206-3p* or *hsa-miR-381-3p* on the translational repression by using a *KLF4*-3'UTR luciferase translational reporter assay. Transfection of miR-mimic-206-3p increased precipitated *KLF4* transcripts by 4.14-fold compared to the non-targeting miR-mimic control, whereas transfection of

**A*****KLF4* Transcript (NM\_004235.5) :****Putative *hsa-miR-206-3p* target sites:**

Position 206-228 of *KLF4* 3'UTR 5' ...GACUGGAUCUUCUAU-CAUUC...  
*hsa-miR-206-3p* 3' | : |||: | |||||





GGUGUGUGAAGGAAUGUAAGGU

**Putative *hsa-miR-381-3p* target sites:**

Position 372-392 of *KLF4* 3'UTR 5' ...AGCAUAAAAGAUACCUUGUAU...  
*hsa-miR-381-3p* 3' :|| | | | |||||  
 UGUCUCUGAACGGGAACAUAU

Position 778-798 of *KLF4* 3'UTR 5' ...AAGCAAACGUCUAUUUGUAU...  
*hsa-miR-381-3p* 3' | : | | | :||| |

UGUCUCUGAACGGGAACAUAU

**B****D****C****E**


**Figure 5.** The *KLF4* transcript is a target of either *hsa-miR-206-3p* or *hsa-miR-381-3p*. (A) Alignment of the *KLF4*-3'UTR region indicating putative *hsa-miR-206-3p* and *hsa-miR-381-3p* binding sites. Seed sequences of *hsa-miR-206-3p* and *hsa-miR-381-3p* are underlined. Endogenous *KLF4* protein levels in differentiated THP-1 macrophages transfected with 25 nM of miR-mimic (B) or miR-inhibitor (D) were determined by immunoblot.  $\beta$ -Actin served as a loading control. LE: longer exposure. Total RNA isolated from differentiated THP-1 macrophages transfected with 25 nM of miR-mimic (C) or miR-inhibitor (E) determined by *KLF4* TaqMan stem-loop RT-qPCR mRNA assays ( $N=3$ ; bars, SEM) ( $^*p<0.05$ ,  $^{**}p<0.01$ , and  $^{***}p<0.001$ ).

miR-mimic-381-3p increased precipitated *KLF4* transcripts by 8.65-fold compared to the non-targeting control (Figure 6A). These results indicate that the *KLF4* transcript binds to both *hsa-miR-206-3p* and *hsa-miR-381-3p*-containing RISCs.


Furthermore, we addressed the specificity and translational inhibition ability of either *hsa-miR-206-3p* or *hsa-miR-381-3p* on the *KLF4* mRNA transcript using the *KLF4*-3'UTR luciferase reporter assay. Transfection of miR-mimic-206-3p decreased *KLF4*-3'UTR luciferase reporter activities by 1.60-fold whereas transfection of miR-mimic-381-3p downregulated the *KLF4*

luciferase reporter activities by 1.67-fold compared to the cells transfected with miR-mimic-Ctl (Figure 6B). In addition, transfection of either miR-inhibitor-206-3p or miR-inhibitor-381-3p increased the *KLF4* luciferase reporter activities by 1.90-fold and 1.66-fold, respectively, when compared to transfection of miR-inhibitor-control (Figure 6C). Because both *hsa-miR-206-3p* and *hsa-miR-381-3p* are capable of repressing *KLF4*-3'UTR translational reporter activities, these data indicate that the *KLF4* transcript is, in fact, a direct target of both *hsa-miR-206-3p* and *hsa-miR-381-3p* in differentiated macrophages.


A



B



C



**Figure 6.** Both *hsa-miR-206-3p* and *hsa-miR-381-3p* bind to endogenous human *KLF4* transcripts in differentiated THP-1 macrophages. (A) Differentiated THP-1 macrophages were transfected with 25nM of indicated miR-mimics or nontargeting miR-mimic-Ctl for 24h. The cells were collected and immunoprecipitated using the panAGO or isotype IgG antibody after 24h transfection. RNA was isolated and the fold enrichment of *KLF4* transcript was measured ( $N=3$ ; bars, SEM). (B) Differentiated THP-1 macrophages were cotransfected with *KLF4*-3'UTR luciferase reporter and 25nM of indicated miR-mimics or nontargeting miR-mimic-Ctl. After 24h, the luciferase activities were measured by the Dual-Glo assay kit ( $N=3$ ; bars, SEM). (C) Differentiated THP-1 macrophages were cotransfected with *KLF4*-3'UTR luciferase reporter and 25nM of indicated miR-inhibitors or nontargeting control. After 24h, the luciferase activities were measured by the Dual-Glo assay kit ( $N=3$ ; bars, SEM). (\* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.001$ ); AGO: argonate protein.

#### *Either hsa-miR-206-3p or hsa-miR-381-3p indirectly regulates M2 macrophage-associated markers and chemokines in differentiated THP-1 macrophages*

In the preceding experiments, we demonstrated that both *hsa-miR-206-3p* and *hsa-miR-381-3p* may regulate the expression of M2 macrophage-associated markers (Figures 3 and 4). The ability of *hsa-miR-206-3p* and *hsa-miR-381-3p* to regulate M2 markers *CD206* and *TGM2* as well as *CCL17*, *CCL22* and *CCL24* expression may either be through direct binding to the 3'UTR of these marker and chemokine transcripts or through other indirect regulatory mechanisms. To determine possible direct interactions between *hsa-miR-206-3p* and *hsa-miR-381-3p* and the M2 macrophage-associated marker and chemokine transcripts, we first used the *in silico* algorithm TargetScanHuman 8.0 to retrieve candidate miRs that


are predicted to target human *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcripts (Supplemental Tables 1–5). TargetScanHuman 8.0 predicted that *hsa-miR-206-3p*, but not *hsa-miR-381-3p*, can target the *TGM2*-3'UTR (Supplemental Table 2) and *CCL22*-3'UTR (Supplemental Table 4), whereas neither *hsa-miR-206-3p* nor *hsa-miR-381-3p* were predicted to bind the 3'UTRs of *CD206*, *CCL17*, and *CCL24* transcripts (Supplemental Tables 1, 3, and 5). To further support the predicted interaction of the *TGM2*-3'UTR as one of the *hsa-miR-206-3p* targets, we used several *in silico* algorithms including *DIANA*, *miRanda*, *PicTar*, *PITA*, and *RNA22*. However, the *miRanda*, *PicTar*, *PITA*, and *RNA22* algorithms failed to predict any miR-mRNA interaction between the *TGM2*-3'UTR and *hsa-miR-206-3p* (data not shown). Similarly, neither *hsa-miR-206-3p* nor *hsa-miR-381-3p* were predicted to exhibit binding between any 3'UTRs of *CD206*, *CCL17*, and *CCL24*

transcripts when analysed by *DIANA*, *miRanda*, *PicTar*, *PITA*, and *RNA22* (data not shown). Further analysis of the human *TGM2* transcript (NM\_004613.4) and *CCL22* transcript (NM\_002990.5) using the *in silico* miR-target prediction tools TargetScanHuman 8.0 and miRDB, we have identified one putative *hsa-miR-206-3p* binding site in the 3'UTR of *TGM2* transcript (Figure 7A) and *CCL22* transcript (Figure 7B). To confirm the suggested interaction between *hsa-miR-206-3p* on *TGM2* and *CCL22* transcripts as predicted by TargetScanHuman 8.0 and miRDB in THP-1 macrophages, we performed RISC-IP experiments by using an anti-panAGO antibody. Neither *TGM2* nor *CCL22* mRNA were enriched in RISC-IP of THP-1 macrophages transfected with miR-mimic-206-3p (Figure 7C), suggesting that there is no binding between either *TGM2* or *CCL22* transcripts with *hsa-miR-206-3p* in THP-1 macrophages. Furthermore, we cannot find any experimentally validated record that demonstrates interactions between 3'UTR of either *TGM2* or *CCL22* and *hsa-miR-206-3p* using miR-mRNA interaction databases, *DIANA-TarBase* v8.0. Based on the combination of *in silico*


miR-mRNA interaction analysis and RISC-IP experiments, we conclude that M2 macrophage-associated markers and chemokines *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcripts are not directly targeted by either *hsa-miR-206-3p* or *hsa-miR-381-3p* in THP-1 macrophages. Therefore, the demonstrated ability of *hsa-miR-206-3p/hsa-miR-381-3p* to upregulate M2 macrophage-associated markers and chemokines *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcripts likely utilises indirect regulatory mechanisms, such as targeting other important signalling molecules or transcription factors (i.e. *KLF4*), which leads to transcriptional activation of these genes.

**Either hsa-miR-206-3p or hsa-miR-381-3p regulates endogenous M2 macrophage-associated markers and chemokines CD206, TGM2, CCL17, CL22, and CCL24 transcript levels partially through KLF4-mediated transcriptional activation**

To determine whether the observed *hsa-miR-206-3p* and/or *hsa-miR-381-3p*-mediated M2 macrophage-associated marker



**Figure 7.** *hsa-miR-206-3p* does not target either human *TGM2* or *CCL22* transcript in THP-1 macrophages. (A) Alignment of the *TGM2*-3'UTR region indicating putative *hsa-miR-206-3p* binding sites. Seed sequence of *hsa-miR-206-3p* is underlined. (B) Alignment of the *CCL22*-3'UTR region indicating putative *hsa-miR-206-3p* binding sites. Seed sequence of *hsa-miR-206-3p* is underlined. (C) Differentiated THP-1 macrophages were transfected with 25 nM of indicated miR-mimics or nontargeting miR-mimic-Ctl for 24 h. The cells were collected and immunoprecipitated using the panAGO or isotype IgG antibody after 24 h transfection. RNA was isolated from the RISC as indicated in either miR-mimic-206-3p or miR-mimic-Ctl transfected THP-1 macrophages by *miRVana*<sup>TM</sup> miR isolation kit, reverse transcribed, and the fold enrichment of either *TGM2* or *CCL22* transcript was measured by TaqMan RT-qPCR ( $N=3$ ; bars, SEM).



**Figure 8.** KLF4 overexpression increases M2 macrophage-associated markers and chemokines in differentiated THP-1 macrophages. Differentiated macrophages were transfected with 2.5  $\mu$ g of either pCMV-Entry-KLF4 or pCMV-Entry vector plasmids for 48 h. Total RNA was isolated from plasmids transfected THP-1 macrophages by *miRVana*<sup>TM</sup> miR isolation kit, reverse transcribed, and subjected to TaqMan RT-qPCR. Endogenous M2 macrophage-associated markers (A) *KLF4* (B) *CD206*, (C) *TGM2*, (D) *CCL17* (E) *CCL22*, and (F) *CCL24* mRNA levels were determined by RT-qPCR ( $N=3$ ; bars, SEM). (\* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.001$ ).

gene upregulation (Figure 3) proceeds via KLF4-mediated transcriptional control, we performed both a gain-of-function study by overexpression of KLF4 and a loss-of-function study by using a KLF4 small molecule chemical inhibitor, kenpau lone, to repress KLF4 and KLF4 associated transcriptional activation in miR-inhibitor-206-3p and miR-inhibitor-381-3p transfected THP-1 macrophages. To investigate whether KLF4 can mediate M2 macrophage marker gene transcription as previously reported (Lin et al. 2023), we determined M2 macrophage-associated markers and chemokines *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* expression using an *in vitro* KLF4 overexpression model. Compared to pCMV-Entry vector control transfected THP-1 macrophages, transfection of KLF4 overexpression plasmid successfully upregulates transgene *KLF4* transcript levels by 9015.2-fold (Figure 8A), whereas the *KLF4* transgene significantly induced endogenous *CD206*, *TGM2*, *CCL17*, *CCL22* and *CCL24* mRNAs by 4.14-, 4.38-, 4.03-, 7.25-, and 2.40-fold, respectively (Figure 8B-F). These results suggest that KLF4 may regulate M2 macrophage-associated markers and chemokines *CD206*, *TGM2*, *CCL17*, *CCL22* and *CCL24* expression.


Consistent with the finding that miR-inhibitors-206-3p and -381-3p upregulate M2 macrophage-associated transcriptional factor *KLF4* as well as M2 macrophage-associated markers and chemokines *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* mRNA in THP-1 macrophages (Figure 3), independent transfections of miR-inhibitor-206-3p and miR-inhibitor-381-3p upregulate endogenous *KLF4* transcripts by 1.78- and 1.77-fold, respectively (Fig. 9A). Furthermore, transfection of miR-inhibitor-206-3p upregulates *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* by 5.68-, 10.3-, 8.95-, 3.31- and 3.15-fold, respectively, whereas transfection of miR-inhibitor-381-3p upregulates *CD206*, *TGM2*, *CCL17*, *CCL22* and *CCL24* by 4.55-, 6.68-, 7.14-, 2.53- and 2.87-fold, respectively (Figure 9B-F). Similar to the finding that treatment with the small molecule KLF4 inhibitor kenpau lone downregulates endogenous *KLF4*, *CD206*, *CCL17*, and *CCL22* transcripts in THP-1 macrophages (Figure 2A,B,D, and E), treatment of 1  $\mu$ M kenpau lone significantly downregulated endogenous *KLF4* transcripts by 28.5-fold (Figure 9A), and decreased the endogenous *CD206*, *CCL17* and *CCL22* transcripts by 2.69-, 3.38-, and 4.05-fold, in miR-inhibitor nontargeting control (miR-inhibitor-Ctl) transfected macrophages, respectively (Figure 9B, D, and E).

Furthermore, treatment of kenpaulone attenuated the induction of M2 macrophage-associated transcription factor as well as the marker and chemokine mRNAs by either miR-inhibitor-206-3p or miR-inhibitor-381-3p transfection in THP-1 macrophages (Figure 9A–F). These results indicate that KLF4-mediated signalling is important for *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcriptional activation by inhibition of *hsa-miR-206-3p* and *hsa-miR-381-3p*.


## Discussion

Our previous report showed that the KLF4 transcription factor can be induced by MDI/MDI-GSH exposure both *in vivo* and *in vitro*, and that KLF4 may play an important role as a downstream regulator/effectector for MDI exposure-mediated induction of M2 macrophage-associated markers and

chemokines in macrophages (Lin et al. 2023); however, the detailed molecular mechanism(s) that regulates the induction of KLF4 after MDI-exposure is currently unknown. In the current report, we have identified a potential *hsa-miR-206-3p*/*hsa-miR-381-3p*-regulated posttranscriptional mechanism that may be involved in the induction of KLF4 after MDI/MDI-GSH exposure in macrophages. Previous reports found that the endogenous *hsa-miR-206-3p* and *hsa-miR-381-3p* were downregulated in an *in vitro* MDI-GSH conjugate exposure human THP-1 macrophage model (Lin et al. 2020, 2021). The downregulation of endogenous *hsa-miR-206-3p* and *hsa-miR-381-3p* after MDI exposure results in the induction of M2 macrophage-associated markers and chemokines including *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcripts via upregulation of KLF4 and KLF4-mediated activation of downstream gene transcriptions (Figure 10). Using an *in vitro* THP-1



**Figure 9.** KLF4 inhibition attenuated miR-inhibitor-206-3p and miR-inhibitor-381-3p transfection-mediated induction of M2 macrophage-associated marker and chemokine expression in differentiated THP-1 macrophages. The differentiated THP-1 macrophages were treated either with 1  $\mu$ M of Kenpaulone or vehicle for 24h followed by transfection of either miR-inhibitor-206-3p, miR-inhibitor-381-3p or nontargeting miR-inhibitor-control (Ctl) for 24h. Total RNA were isolated from THP-1 macrophages with indicated treatments/transfactions by *miRVana*™ miR isolation kit, reverse transcribed, and subjected to TaqMan stem-loop RT-qPCR. The endogenous M2 macrophage-associated transcription factor (A) *KLF4*, markers (B) *CD206*, (C) *TGM2*, (D) *CCL17*, (E) *CCL22*, and (F) *CCL24* mRNA levels were determined in total RNA isolated from THP-1 macrophages ( $N=3$ ; bars, SEM). Vehicle (Ctl): RPMI-1640 media containing 10% FBS and 0.01% DMSO. MDI: 4,4'-methylene diphenyl diisocyanate. GSH: Glutathione. (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  when compared to vehicle treated macrophages with transfection of miR-inhibitor-Ctl; # $p < 0.05$ , ## $p < 0.01$ , ### $p < 0.001$ , when compared to macrophages treated with vehicle followed by 10  $\mu$ M MDI-GSH conjugate exposure as well as with transfection of indicated either miR-inhibitor-206-3p or miR-inhibitor-381-3p).



**Figure 10.** Proposed mechanisms by which MDI exposure induces M2 macrophage-associated markers and chemokine CCL17, CCL22, and CCL24, via *hsa-miR-206-3p/hsa-miR-381-3p* regulated KLF4 activation in macrophages. MDI: 4,4'-methylene diphenyl diisocyanate; TFs: transcription factors; CDS: coding sequences; KLF4: Krüppel-like factor 4. Note: Some illustrated schematics were obtained from motifolio templates ([www.motifolio.com](http://www.motifolio.com)), Accessed 21 January 2024) or openclipart website ([www.openclipart.org](http://www.openclipart.org)), Accessed 21 January 2024.

macrophage culture model, we have identified that both *hsa-miR-206-3p* and *hsa-miR-381-3p* target the *KLF4* mRNA transcript which suppresses *KLF4* translation and decreases *KLF4* mRNA levels in macrophages (Figure 5). Although the *KLF4* transcript has been reported to be a target of *hsa-miR-206-3p* in many different cell types (Lin et al. 2011; Parasramka et al. 2012; Tang et al. 2013; Sharma et al. 2014; Qinglei et al. 2015; Wang et al. 2021); to our knowledge, this report is the first to confirm that the *KLF4* transcript is a target of *hsa-miR-381-3p*.

Dysfunction of macrophages that are regulated by *KLF4*-mediated molecular changes in signals, cellular processes, and polarisation status may participate in the pathogenesis of different diseases such as asthma and alcoholic liver disease (ALD). Previous reports have revealed that the role of *KLF4* in the monocytes/macrophages is associated with pathophysiological development of allergic asthma by promoting airway inflammation and airway remodelling (Nimpong et al. 2017). *KLF4* has been demonstrated to promote monocyte differentiation *in vivo* (Alder et al. 2008). Furthermore, Liao et al. determined that *KLF4* is strongly induced in M2 macrophages by IL4/IL13 activated STAT6 signalling whereas its expression is reduced by LPS-mediated NF- $\kappa$ B inhibition in M1 macrophages (Liao et al. 2011). Moreover, *KLF4*-deficient macrophages display increased pro-inflammatory cytokine expression which is associated with an M1 macrophage phenotype (Liao et al. 2011). These observations indicate a crucial role for *KLF4* in promoting resting macrophage (M0) population polarisation towards the M2 phenotype. Saha et al. showed that *KLF4* overexpression was associated with elevated CD163 $^{+}$ /CD206 $^{+}$  M2 macrophage populations in an *in vivo* ALD mouse model, and *KLF4* has been identified as one important transcriptional regulator for M2 macrophage polarisation. (Saha et al. 2015).

We note that the M2 macrophage population has been found to be increased in asthma. Girodet et al. compared the phenotype and function of bronchoalveolar lavage fluid (BALF) macrophages/alveolar macrophages from healthy control subjects to subjects with asthma and found that the alveolar macrophages isolated from BALF of subjects with asthma expressed high levels of M2 macrophage-associated markers CD206 and MHCII, when compared to control subjects (Girodet et al. 2016). *In vitro* functional studies reveal that the M2 macrophages have elevated IL-6, IL-10, and IL-12p40 production and can modulate dendritic and CD4 $^{+}$  T-cell interactions. These reports suggest that the role of *KLF4* may be associated with promoting M2 macrophage-associated marker expression in asthma. Ultimately, *KLF4* may promote asthma pathogenesis through mediating M2 macrophage polarisation and macrophage induced recruitment of immune cells into the lung microenvironment and sustaining local inflammation within the lung.

Our previous study employed gain- and loss-of-function strategies using *KLF4* overexpression plasmid transfection and *KLF4* siRNA knockdown, respectively, to demonstrate that *KLF4* plays an important role in regulating the M2 macrophage-associated markers CD206 and TGM2 as well as chemokines CCL17, CCL22 and CCL24 (Lin et al. 2023). The current report employs a different strategy to conduct the loss-of-function study by using a *KLF4* small molecule inhibitor, kenpaullone, to inhibit *KLF4* function (Figure 2). Both siRNA- and kenpaullone-mediated *KLF4* inhibition demonstrated similar regulatory effects on M2 macrophage-associated marker and chemokine expression. The primary mechanism by which siRNAs and miRs can interfere with specific gene silencing/RNA degradation/translation inhibition involves the interactions between siRNAs or miRs with the RISC to the siRNA or miR targeted sequences

in the gene transcript (Lam et al. 2015). One major aim of the current study was to examine whether miRs can post-transcriptionally regulate KLF4 expression, and the siRNA strategy previously used to knockdown KLF4 (Lin et al. 2023) could introduce artefacts that allow exogenous KLF4 siRNAs to compete with endogenous miRs to bind RISC proteins and KLF4 transcripts; thus, we employed a loss-of function study by treatment with kenpauallone, a specific KLF4 small chemical inhibitor, instead of using specific KLF4 siRNAs to knockdown the endogenous KLF4 level in the THP-1 macrophages (Figures 2 and 9). Consistent with our previous observations, kenpauallone treatment significantly downregulates the endogenous *KLF4* as well as the endogenous *CD206*, *CCL17* and *CCL22* transcripts whereas the expression of *TGM2* and *CCL24* transcripts are unaffected (Figure 2). These results further strengthen our previous observation that *KLF4* may directly regulate the transcription of *CD206*, *CCL17* and *CCL22* whereas the expression of *TGM2* and *CCL24* transcripts are indirectly regulated by other transcription factors that may be activated by KLF4-mediated signalling in the macrophages.

Molecular mediators that regulate KLF4 expression and function in macrophages may play important roles in the pathogenesis of many diseases including asthma development. Among these molecular mediators, miRs have been found to play a crucial role in regulating KLF4 expression. MiRs regulate many cell functions in normal cell homeostasis and disease states by affecting diverse signalling pathways through negative regulation of target genes. For miR-mediated KLF4 signalling regulation, including the two miRs *hsa-miR-206-3p* and *hsa-miR-381-3p* that are observed to regulate *KLF4* in the current study. Currently, the following miRs have been suggested to post-transcriptionally regulate *KLF4* in cells under either normal or disease conditions, *miRs-7, -9-5p, -10a, -10b, -15a, -25, -29a, -34a, -103/107, -137, -143, -145, -146a, -152, -200c, -206, -429, -200, and -2909* (Xu et al. 2009; Davis-Dusenberry et al. 2011; Lin et al. 2011; Chen et al. 2012; Jiang et al. 2013; Sureban et al. 2013; Ma et al. 2014; Malik et al. 2014; Meza-Sosa et al. 2014; Tang et al. 2014; Xiao et al. 2014; Tabrizi et al. 2015; Dong et al. 2019; Zhang et al. 2023). In asthma, Xu et al. revealed that the level of *hsa-miR-206-3p* from peripheral blood mononuclear cells (PBMCs) of asthmatic children in the attack stage were significantly lower than those in healthy children, whereas the KLF4 levels from PBMCs of asthmatic children were significantly higher than control (Qinglei et al. 2015). Our previous studies have shown that endogenous levels of *hsa-miR-206-3p* and *hsa-miR-381-3p* were downregulated in both BALCs isolated from mice exposed to MDI dust and differentiated THP-1 macrophages exposed to MDI-GSH conjugates, resulting in induced endogenous *iNOS*, *CCL2*, *CCL3*, *CCL5*, and *CXCL8* transcription partially through calcineurin mediated signalling activation (Lin et al. 2020, 2021). Through *in silico* miR targeting analysis, we identified that the human *KLF4* 3'UTR contains both *hsa-miR-206-3p* and *hsa-miR-381-3p* binding sites (Figure 5A). We further confirmed that human KLF4 can be regulated by either endogenous *hsa-miR-206-3p* or *hsa-miR-381-3p* in macrophages through loss- or gain-of-functional analysis (Figures 5 and 6). Given that we identified

that *KLF4* transcripts can be post-transcriptionally regulated by either *hsa-miR-206-3p* or *hsa-miR-381-3p*, and that many other miRs have been shown to regulate KLF4, and that KLF4 plays an important role in regulating macrophage polarisation (Lawrence and Natoli 2011; Tugal et al. 2013); it will be interesting to investigate whether MDI-exposure mediates other miR responses that may play major regulatory roles in MDI-OA pathogenesis.

Mechanistic studies to understand how MDI/MDI-GSH conjugate exposure downregulates endogenous *hsa-miR-206-3p* and *hsa-miR-381-3p* in macrophages to initiate MDI/MDI-GSH mediated induction of *KLF4* and downstream KLF4-mediated M2 macrophage-associated marker responses are not currently available. The endogenous miR levels can be regulated *via* biosynthesis and degradation (Bartel 2018). At biosynthesis regulation of either *hsa-miR-206-3p* or *hsa-miR-381-3p*, recent reports suggest that the transcription factor Myocardin Related Transcription Factor A (MRTF-A) promotes the biosynthesis of *hsa-miR-206-3p* through binding to the promoter region of *MIR206* gene and activating its transcription in breast cancer cells (Xiang et al. 2017), whereas the transcription factor B cell receptor-associated protein 31 (BAP31) has been reported to inhibit *hsa-miR-206-3p* expression in colorectal cancer (Zhang et al. 2023). Zhou and his colleagues revealed that the histone methyltransferase, enhancer of zeste homolog 2 (EZH2), repressed *hsa-miR-381-3p* by promoting H3K27me3 signature on histone H3, deactivating *MIR381* promoter activities through histone methylation in hepatocellular cancer (Zhou et al. 2022). Furthermore, the degradation/inhibition of *hsa-miR-206-3p* and *hsa-miR-381-3p* was found to be regulated by various linear long non-coding RNAs (lncRNAs) or circular RNAs (circRNAs) which bind the miRs through miR response elements (MRE) that exist in the lncRNA/circRNA sequences (Salmena et al. 2011; Chiu et al. 2018). The linear lncRNAs that can bind to endogenous *hsa-miR-206-3p* in many different cell types include *lncRNA\_HOTAIR* (Shengnan et al. 2020), *lncRNA\_UCA1* (Li et al. 2019), *lncRNA\_SNHG14* (Zhao et al. 2020), *lncRNA\_MALAT1* (Tang et al. 2018), and *lncRNA\_ROR* (Fei et al. 2019), etc., while *hsa-miR-381-3p* binding linear lncRNAs include *lncRNA\_CAT104* (Xia et al. 2018; Yuan et al. 2018), *lncRNA\_DLEU1* (Gao et al. 2019), *lncRNA\_TUG1* (Zhang et al. 2017), etc. The endogenous circular RNAs that bind *hsa-miR-206-3p* includes *hsa\_circ\_0000199* (Li et al. 2021), *hsa\_circ\_0008726* (Han et al. 2022; Zhang et al. 2022), *hsa\_circ\_0056618* (Li et al. 2018; Zheng et al. 2020), *hsa\_circ\_0057558* (Ding et al. 2021), etc., while *hsa-miR-381-3p* sponging circRNAs including *hsa\_circ\_0000284* (Bi et al. 2021), *hsa\_circ\_0084003* (Zhang et al. 2019) and *hsa\_circ\_0099188* (Sun et al. 2022). In addition, the expression of *hsa-miR-381-3p* can be regulated by several molecules including Periostin (Hu et al. 2017), EZH2 (Dou et al. 2019), and WISP-1 (Tsai et al. 2017). Whether or not MDI/MDI-GSH exposure in macrophages can activate or inhibit regulators involved in the biosynthesis or degradation of *hsa-miR-206-3p* and *hsa-miR-381-3p* in macrophages will need to be the subject of future study.

Strengths of the current *in vitro* THP-1 macrophage MDI/MDI-GSH exposure model include the ability to perform gain- or

loss-of-function experiments with miR mimics/inhibitors, *KLF4* transgenes, and *KLF4*-3'UTR luciferase reporter assays with identical genetics from a single cell type to investigate the underlying molecular mechanism that regulates MDI/MDI-GSH mediated effects. However, one inherent limitation of the model is that it leaves uncertain whether or not the identified miR-mediated *KLF4* and *KLF4*-mediated M2 macrophage-associated marker and chemokine mechanism reflects similar lung immune responses, that may participate in the early steps in asthma pathogenesis in the real-world workers with MDI-OA. Future studies will be needed to better elucidate potential connections of diisocyanate exposure with the identified molecular miR regulatory mechanisms in real-world MDI workers.

## Conclusion

In conclusion, this report implicates *hsa-miR-206-3p* and *hsa-miR-381-3p* as important post-transcriptional regulators of *KLF4* transcripts and *KLF4*-mediated signalling, ultimately targeting M2 macrophage-associated markers and chemokine transcription in macrophages after MDI/MDI-GSH conjugate exposure. Decreased expression of *hsa-miR-206-3p* and *hsa-miR-381-3p* was observed following MDI-GSH conjugate exposure in an *in vitro* human THP-1 macrophage *in vitro* model. This miR-regulated mechanism may contribute to the upregulation of M2 macrophage-associated markers and chemokines including *CD206*, *TGM2*, *CCL17*, *CCL22*, and *CCL24* transcription in the macrophages following MDI/MDI-GSH exposure through upregulation of M2 macrophage-associated transcriptional factor, *KLF4*.

## Disclosure statement

The authors declare that they have no conflicting financial interests. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the National Institute for Occupational Safety and Health, Centres for Disease Control and Prevention.

## Funding

This work was supported by intramural funds (CAN#19390BN8 and #39390KK5) from the National Institute for Occupational Safety and Health, Centres for Disease Control and Prevention.

## ORCID

Chen-Chung Lin  <http://orcid.org/0000-0001-5686-2169>  
 Brandon F. Law  <http://orcid.org/0000-0002-3658-6547>  
 Justin M. Hettick  <http://orcid.org/0000-0002-9143-1513>

## Data availability statement

Data available within the article or its supplementary tables.

## References

- Agarwal V, Bell GW, Nam J-W, Bartel DP. 2015. Predicting effective microRNA target sites in mammalian mRNAs. *eLife*. 4:e05005. doi: [10.7554/eLife.05005](https://doi.org/10.7554/eLife.05005).
- Environmental Protection Agency. USEPA. 2011. Methylene Diphenyl Diisocyanate (MDI) And Related Compounds Action Plan. <https://www.epa.gov/sites/default/files/2015-09/documents/mdi.pdf>
- Alder JK, Georgantas RW, 3rd, Hildreth RL, Kaplan IM, Morisot S, Yu X, McDevitt M, Civin CI. 2008. Kruppel-like factor 4 is essential for inflammatory monocyte differentiation *in vivo*. *J Immunol*. 180(8):5645–5652. doi: [10.4049/jimmunol.180.8.5645](https://doi.org/10.4049/jimmunol.180.8.5645).
- Allport DC, Gilbert DS, Outterside SM. 2003. MDI and TDI: a safety, health and the environment: a source book and practical guide. New York: j. Wiley.
- Barnes PJ. 2008. Immunology of asthma and chronic obstructive pulmonary disease. *Nat Rev Immunol*. 8(3):183–192. doi: [10.1038/nri2254](https://doi.org/10.1038/nri2254).
- Bartel DP. 2018. Metazoan microRNAs. *Cell*. 173(1):20–51.
- Baxter EW, Graham AE, Re NA, Carr IM, Robinson JI, Mackie SL, Morgan AW. 2020. Standardized protocols for differentiation of THP-1 cells to macrophages with distinct M(IFN $\gamma$ +LPS), M(IL-4) and M(IL-10) phenotypes. *J Immunol Methods*. 478:112721. doi: [10.1016/j.jim.2019.112721](https://doi.org/10.1016/j.jim.2019.112721).
- Bernstein DL, Korbee L, Stauder T, Bernstein JA, Scinto J, Herd ZL, Bernstein IL. 1993. The low prevalence of occupational asthma and antibody-dependent sensitization to diphenylmethane diisocyanate in a plant engineered for minimal exposure to diisocyanates. *J Allergy Clin Immunol*. 92(3):387–396. doi: [10.1016/0091-6749\(93\)90117-x](https://doi.org/10.1016/0091-6749(93)90117-x).
- Bi L, Zhang C, Yao Y, He Z. 2021. Circ-HIPK3 regulates YAP1 expression by sponging miR-381-3p to promote oral squamous cell carcinoma development. *J Biosci*. 46(1). doi: [10.1007/s12038-021-00142-w](https://doi.org/10.1007/s12038-021-00142-w).
- Boonpiyathad T, Sözener ZC, Satitsuksanoa P, Akdis CA. 2019. Immunologic mechanisms in asthma. *Semin Immunol*. 46:101333. doi: [10.1016/j.smim.2019.101333](https://doi.org/10.1016/j.smim.2019.101333).
- Chen J, Wang G, Lu C, Guo X, Hong W, Kang J, Wang J. 2012. Synergetic cooperation of microRNAs with transcription factors in iPS cell generation. *PLoS One*. 7(7):e40849. doi: [10.1371/journal.pone.0040849](https://doi.org/10.1371/journal.pone.0040849).
- Chiu HS, Martínez MR, Komissarova EV, Llobet-Navas D, Bansal M, Paull EO, Silva J, Yang X, Sumazin P, Califano A. 2018. The number of titrated microRNA species dictates ceRNA regulation. *Nucleic Acids Res*. 46(9):4354–4369. doi: [10.1093/nar/gky286](https://doi.org/10.1093/nar/gky286).
- Davis-Dusenberry BN, Chan MC, Reno KE, Weisman AS, Layne MD, Lagna G, Hata A. 2011. down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. *J Biol Chem*. 286(32):28097–28110. doi: [10.1074/jbc.M111.236950](https://doi.org/10.1074/jbc.M111.236950).
- Ding T, Zhu Y, Jin H, Zhang P, Guo J, Zheng J. 2021. Circular RNA circ\_0057558 controls prostate cancer cell proliferation through regulating miR-206/USP33/c-Myc axis. *Front Cell Dev Biol*. 9:644397. doi: [10.3389/fcell.2021.644397](https://doi.org/10.3389/fcell.2021.644397).
- Dong X, Wang F, Xue Y, Lin Z, Song W, Yang N, Li Q. 2019. MicroRNA-9-5p downregulates Klf4 and influences the progression of hepatocellular carcinoma via the AKT signaling pathway. *Int J Mol Med*. 43(3):1417–1429. doi: [10.3892/ijmm.2019.4062](https://doi.org/10.3892/ijmm.2019.4062).
- Dou D, Ge X, Wang X, Xu X, Zhang Z, Seng J, Cao Z, Gu Y, Han M. 2019. EZH2 contributes to Cisplatin resistance in breast cancer by epigenetically suppressing miR-381 Expression. *Onco Targets Ther*. 12:9627–9637. doi: [10.2147/OTT.S214104](https://doi.org/10.2147/OTT.S214104).
- Engfeldt M, Isaksson M, Zimerson E, Bruze M. 2013. Several cases of work-related allergic contact dermatitis caused by isocyanates at a company manufacturing heat exchangers. *Contact Dermatitis*. 68(3): 175–180. doi: [10.1111/j.1600-0536.2012.02167.x](https://doi.org/10.1111/j.1600-0536.2012.02167.x).
- Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. 2003. MicroRNA targets in drosophila. *Genome Biol*. 5(1):R1. doi: [10.1186/gb-2003-5-1-r1](https://doi.org/10.1186/gb-2003-5-1-r1).
- Fei D, Sui G, Lu Y, Tan L, Dongxu Z, Zhang K. 2019. The long non-coding RNA-ROR promotes osteosarcoma progression by targeting miR-206. *J Cell Mol Med*. 23(3):1865–1872. doi: [10.1111/jcmm.14087](https://doi.org/10.1111/jcmm.14087).
- Fricker M, Gibson PG. 2017. Macrophage dysfunction in the pathogenesis and treatment of asthma. *Eur Respir J*. 50(3):1700196. doi: [10.1183/13993003.00196-2017](https://doi.org/10.1183/13993003.00196-2017).
- Gao S, Cai Y, Zhang H, Hu F, Hou L, Xu Q. 2019. Long noncoding RNA DLEU1 aggravates pancreatic ductal adenocarcinoma carcinogenesis

- via the miR-381/CXCR4 axis. *J Cell Physiol.* 234(5):6746–6757. doi: [10.1002/jcp.27421](https://doi.org/10.1002/jcp.27421).
- Ghaleb AM, Yang VW. 2017. Kruppel-like factor 4 (KLF4): What we currently know. *Gene.* 611:27–37. doi: [10.1016/j.gene.2017.02.025](https://doi.org/10.1016/j.gene.2017.02.025).
- Girodet PO, Nguyen D, Mancini JD, Hundal M, Zhou X, Israel E, Cernadas M. 2016. Alternative macrophage activation is increased in asthma. *Am J Respir Cell Mol Biol.* 55(4):467–475. doi: [10.1165/rcmb.2015-0295OC](https://doi.org/10.1165/rcmb.2015-0295OC).
- Gregory RL, Chendrimada TP, Cooch N, Shiekhattar R. 2005. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. *Cell.* 123(4):631–640. doi: [10.1016/j.cell.2005.10.022](https://doi.org/10.1016/j.cell.2005.10.022).
- Han T, Shi M, Chen G, Hao J. 2022. Circ\_0008726 promotes malignant progression of ESCC cells through miR-206/HOXA13 pathway. *Gen Thorac Cardiovasc Surg.* 71(1):33–45. doi: [10.1007/s11748-022-01874-8](https://doi.org/10.1007/s11748-022-01874-8).
- Holgate ST. 2008. Pathogenesis of asthma. *Clin Exp Allergy.* 38(6):872–897. doi: [10.1111/j.1365-2222.2008.02971.x](https://doi.org/10.1111/j.1365-2222.2008.02971.x).
- Hu WW, Chen PC, Chen JM, Wu YM, Liu PY, Lu CH, Lin YF, Tang CH, Chao CC. 2017. Periostin promotes epithelial-mesenchymal transition via the MAPK/miR-381 axis in lung cancer. *Oncotarget.* 8(37):62248–62260. doi: [10.18632/oncotarget.19273](https://doi.org/10.18632/oncotarget.19273).
- Huang HY, Lin YC, Li J, Huang KY, Shrestha S, Hong HC, Tang Y, Chen YG, Jin CN, Yu Y, et al. 2020. miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. *Nucleic Acids Res.* 48(D1):D148–d154.
- Inui M, Martello G, Piccolo S. 2010. MicroRNA control of signal transduction. *Nat Rev Mol Cell Biol.* 11(4):252–263. doi: [10.1038/nrm2868](https://doi.org/10.1038/nrm2868).
- Jan RL, Chen SH, Chang HY, Yeh HJ, Shieh CC, Wang JY. 2008. Asthma-like syndrome in school children after accidental exposure to xylene and methylene diphenyl diisocyanate. *J Microbiol Immunol Infect.* 41(4):337–341.
- Jiang K, Ren C, Nair VD. 2013. MicroRNA-137 represses Klf4 and Tbx3 during differentiation of mouse embryonic stem cells. *Stem Cell Res.* 11(3):1299–1313. doi: [10.1016/j.scr.2013.09.001](https://doi.org/10.1016/j.scr.2013.09.001).
- Jones K, Johnson PD, Baldwin PEJ, Coldwell M, Cooke J, Keen C, Harding AH, Smith D, Cocker J. 2017. Exposure to diisocyanates and their corresponding diamines in seven different workplaces. *Ann Work Expo Health.* 61(3):383–393. doi: [10.1093/annweh/wxx006](https://doi.org/10.1093/annweh/wxx006).
- Karagkouni D, Paraskevopoulou MD, Chatzopoulos S, Vlachos IS, Tatsoglou S, Kanellos I, Papadimitriou D, Kavakiotis I, Maniou S, Skoufos G, et al. 2018. DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions. *Nucleic Acids Res.* 46(D1):D239–d245. doi: [10.1093/nar/gkx1141](https://doi.org/10.1093/nar/gkx1141).
- Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. 2007. The role of site accessibility in microRNA target recognition. *Nat Genet.* 39(10):1278–1284. doi: [10.1038/ng2135](https://doi.org/10.1038/ng2135).
- Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, et al. 2005. Combinatorial microRNA target predictions. *Nat Genet.* 37(5):495–500. doi: [10.1038/ng1536](https://doi.org/10.1038/ng1536).
- Lam JK, Chow MY, Zhang Y, Leung SW. 2015. siRNA Versus miRNA as Therapeutics for Gene Silencing. *Mol Ther Nucleic Acids.* 4(9):e252. doi: [10.1038/mtna.2015.23](https://doi.org/10.1038/mtna.2015.23).
- Lawrence T, Natoli G. 2011. Transcriptional regulation of macrophage polarization: enabling diversity with identity. *Nat Rev Immunol.* 11(11):750–761. doi: [10.1038/nri3088](https://doi.org/10.1038/nri3088).
- Li Y, Wen H, Yang J, Zhou Y, Cheng X. 2019. Boosting oxygen reduction catalysis with N, F, and S tri-doped porous graphene: tertiary N-precursors regulates the constitution of catalytic active sites. *Carbon.* 142:1–12. doi: [10.1016/j.carbon.2018.09.079](https://doi.org/10.1016/j.carbon.2018.09.079).
- Li H, Xu W, Xia Z, Liu W, Pan G, Ding J, Li J, Wang J, Xie X, Jiang D. 2021. Hsa\_circ\_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling. *Aging (Albany NY).* 13(3):4522–4551. doi: [10.18632/aging.202415](https://doi.org/10.18632/aging.202415).
- Li H, Yao G, Feng B, Lu X, Fan Y. 2018. Circ\_0056618 and CXCR4 act as competing endogenous in gastric cancer by regulating miR-206. *J Cell Biochem.* 119(11):9543–9551. doi: [10.1002/jcb.27271](https://doi.org/10.1002/jcb.27271).
- Li ZY, Zhu YX, Chen JR, Chang X, Xie ZZ. 2023. The role of KLF transcription factor in the regulation of cancer progression. *Biomed Pharmacother.* 162:114661. doi: [10.1016/j.bioph.2023.114661](https://doi.org/10.1016/j.bioph.2023.114661).
- Liao X, Sharma N, Kapadia F, Zhou G, Lu Y, Hong H, Paruchuri K, Mahabeleshwar GH, Dalmas E, Ventecler N, et al. 2011. Kruppel-like factor 4 regulates macrophage polarization. *J Clin Invest.* 121(7):2736–2749. doi: [10.1172/JCI45444](https://doi.org/10.1172/JCI45444).
- Lin CC, Law BF, Hettick JM. 2020. Acute 4,4'-methylene diphenyl diisocyanate exposure-mediated downregulation of miR-206-3p and miR-381-3p activates inducible nitric oxide synthase transcription by targeting calcineurin/NFAT signaling in macrophages. *Toxicol Sci.* 173(1):100–113.
- Lin CC, Law BF, Hettick JM. 2021. MicroRNA-mediated calcineurin signaling activation induces CCL2, CCL3, CCL5, IL8, and chemotactic activities in 4,4'-methylene diphenyl diisocyanate exposed macrophages. *Xenobiotica.* 51(12):1436–1452. doi: [10.1080/00498254.2021.2005851](https://doi.org/10.1080/00498254.2021.2005851).
- Lin CC, Law BF, Hettick JM. 2023. 4,4'-Methylene diphenyl diisocyanate exposure induces expression of alternatively activated macrophage-associated markers and chemokines partially through Kruppel-like factor 4 mediated signaling in macrophages. *Xenobiotica.* 53(12):653–669. doi: [10.1080/00498254.2023.2284867](https://doi.org/10.1080/00498254.2023.2284867).
- Lin CC, Law BF, Siegel PD, Hettick JM. 2019. Circulating miRs-183-5p, -206-3p and -381-3p may serve as novel biomarkers for 4,4'-methylene diphenyl diisocyanate exposure. *Biomarkers.* 24(1):76–90. doi: [10.1080/1354750X.2018.1508308](https://doi.org/10.1080/1354750X.2018.1508308).
- Lin CC, Liu LZ, Addison JB, Wonderlin WF, Ivanov AV, Ruppert JM. 2011. A KLF4-miRNA-206 autoregulatory feedback loop can promote or inhibit protein translation depending upon cell context. *Mol Cell Biol.* 31(12):2513–2527. doi: [10.1128/MCB.01189-10](https://doi.org/10.1128/MCB.01189-10).
- Lofgren DJ, Walley TL, Peters PM, Weis ML. 2003. MDI exposure for spray-on truck bed lining. *Appl Occup Environ Hyg.* 18(10):772–779. doi: [10.1080/10473220301441](https://doi.org/10.1080/10473220301441).
- Lu TP, Lee CY, Tsai MH, Chiu YC, Hsiao CK, Lai LC, Chuang EY. 2012. miRSystem: an integrated system for characterizing enriched functions and pathways of microRNA targets. *PLoS One.* 7(8):e42390. doi: [10.1371/journal.pone.0042390](https://doi.org/10.1371/journal.pone.0042390).
- Lyssiotis CA, Foreman RK, Staerk J, Garcia M, Mathur D, Markoulaki S, Hanna J, Lairson LL, Charette BD, Bouchez LC, et al. 2009. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. *Proc Natl Acad Sci U S A.* 106(22):8912–8917. doi: [10.1073/pnas.0903860106](https://doi.org/10.1073/pnas.0903860106).
- Ma J, Yao Y, Wang P, Liu Y, Zhao L, Li Z, Li Z, Xue Y. 2014. MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Kruppel-like factor 4. *Cancer Lett.* 355(1):85–95. doi: [10.1016/j.canlet.2014.09.012](https://doi.org/10.1016/j.canlet.2014.09.012).
- Maeß MB, Wittig B, Cignarella A, Lorkowski S. 2014. Reduced PMA enhances the responsiveness of transfected THP-1 macrophages to polarizing stimuli. *J Immunol Methods.* 402(1-2):76–81. doi: [10.1016/j.jim.2013.11.006](https://doi.org/10.1016/j.jim.2013.11.006).
- Malik D, Kaul D, Chauhan N, Marwaha RK. 2014. miR-2909-mediated regulation of KLF4: a novel molecular mechanism for differentiating between B-cell and T-cell pediatric acute lymphoblastic leukemias. *Mol Cancer.* 13(1):175. doi: [10.1186/1476-4598-13-175](https://doi.org/10.1186/1476-4598-13-175).
- McGeary SE, Lin KS, Shi CY, Pham TM, Bisaria N, Kelley GM, Bartel DP. 2019. The biochemical basis of microRNA targeting efficacy. *Science.* 366(6472). doi: [10.1126/science.aav1741](https://doi.org/10.1126/science.aav1741).
- Meza-Sosa KF, Pérez-García El, Camacho-Concha N, López-Gutiérrez O, Pedraza-Alva G, Pérez-Martínez L. 2014. MiR-7 promotes epithelial cell transformation by targeting the tumor suppressor KLF4. *PLoS One.* 9(9):e103987. doi: [10.1371/journal.pone.0103987](https://doi.org/10.1371/journal.pone.0103987).
- Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B, Rigoutsos I. 2006. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. *Cell.* 126(6):1203–1217. doi: [10.1016/j.cell.2006.07.031](https://doi.org/10.1016/j.cell.2006.07.031).
- Montecillo-Aguado M, Morales-Martínez M, Huerta-Yepez S, Vega MI. 2021. KLF4 inhibition by Kenpaulone induces cytotoxicity and chemo sensitization in B-NHL cell lines via YY1 independent. *Leuk Lymphoma.* 62(6):1422–1431. doi: [10.1080/10428194.2020.1869960](https://doi.org/10.1080/10428194.2020.1869960).

- Nimpong JA, Gebregziabher W, Singh UP, Nagarkatti P, Nagarkatti M, Hodge J, Liu C, Fan D, Ai W. **2017**. Deficiency of KLF4 compromises the lung function in an acute mouse model of allergic asthma. *Biochem Biophys Res Commun.* 493(1):598–603. doi: [10.1016/j.bbrc.2017.08.146](https://doi.org/10.1016/j.bbrc.2017.08.146).
- NIOSH **1994a**. Letter from NIOSH to Distinctive Designs International Inc. with a study report. Cincinnati, OH: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health.
- NIOSH **1994b**. Letter from NIOSH to Jim Walter Resources, Inc. with a study report. Cincinnati, OH: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health.
- NIOSH **2004**. A Summary of Health Hazard Evaluations: issues Related to Occupational Exposure to Isocyanates, 1989 to 2002.
- Parasramka MA, Dashwood WM, Wang R, Saeed HH, Williams DE, Ho E, Dashwood RH. **2012**. A role for low-abundance miRNAs in colon cancer: the miR-206/Krüppel-like factor 4 (KLF4) axis. *Clin Epigenetics.* 4(1):16. doi: [10.1186/1868-7083-4-16](https://doi.org/10.1186/1868-7083-4-16).
- Park CS, Shen Y, Lewis A, Lacorazza HD. **2016**. Role of the reprogramming factor KLF4 in blood formation. *J Leukoc Biol.* 99(5):673–685. doi: [10.1189/jlb.1RU1215-539R](https://doi.org/10.1189/jlb.1RU1215-539R).
- Qinglei X, Zhu B, Xiaobo M, Zhang W, Liu L, Wang S, Chen J. **2015**. Expression of microRNA-206 in peripheral blood mononuclear cells in asthmatic children. *J Clin Pediatrics.* (2):105–108.
- Redlich CA, Karol MH. **2002**. Diisocyanate asthma: clinical aspects and immunopathogenesis. *Int Immunopharmacol.* 2(2-3):213–224. doi: [10.1016/s1567-5769\(01\)00174-6](https://doi.org/10.1016/s1567-5769(01)00174-6).
- Ren J, Huang HJ, Gong Y, Yue S, Tang LM, Cheng SY. **2014**. MicroRNA-206 suppresses gastric cancer cell growth and metastasis. *Cell Biosci.* 4(1):26. doi: [10.1186/2045-3701-4-26](https://doi.org/10.1186/2045-3701-4-26).
- Saha B, Bala S, Hosseini N, Kodys K, Szabo G. **2015**. Krüppel-like factor 4 is a transcriptional regulator of M1/M2 macrophage polarization in alcoholic liver disease. *J Leukoc Biol.* 97(5):963–973. doi: [10.1189/jlb.4A1014-485R](https://doi.org/10.1189/jlb.4A1014-485R).
- Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. **2011**. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? *Cell.* 146(3):353–358. doi: [10.1016/j.cell.2011.07.014](https://doi.org/10.1016/j.cell.2011.07.014).
- Sharma SB, Lin CC, Farrugia MK, McLaughlin SL, Ellis EJ, Brundage KM, Salkeni MA, Ruppert JM. **2014**. MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1. *Mol Cell Biol.* 34(22):4143–4164. doi: [10.1128/MCB.00480-14](https://doi.org/10.1128/MCB.00480-14).
- Shengnan J, Dafei X, Hua J, Sunfu F, Xiaowei W, Liang X. **2020**. Long non-coding RNA HOTAIR as a competitive endogenous RNA to sponge miR-206 to promote colorectal cancer progression by activating CCL2 [Research Paper]. *J Cancer.* 11(15):4431–4441. doi: [10.7150/jca.42308](https://doi.org/10.7150/jca.42308).
- Sittka A, Schmeck B. **2013**. MicroRNAs in the lung. *Adv Exp Med Biol.* 774:121–134. doi: [10.1007/978-94-007-5590-1\\_7](https://doi.org/10.1007/978-94-007-5590-1_7).
- Statista **2022**. Methylene diphenyl diisocyanate demand worldwide from 2011 to 2021.
- Sun L, Liu J, Sun X, Zhang Y, Cui X. **2022**. CircTRHDE knockdown protects WI-38 cells against LPS-induced inflammatory injury. *Autoimmunity.* 55(4):233–242. doi: [10.1080/08916934.2022.2062595](https://doi.org/10.1080/08916934.2022.2062595).
- Sureban SM, May R, Qu D, Weygant N, Chandrakesan P, Ali N, Lightfoot SA, Pantazis P, Rao CV, Postier RG, et al. **2013**. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. *PLoS One.* 8(9):e73940. doi: [10.1371/journal.pone.0073940](https://doi.org/10.1371/journal.pone.0073940).
- Tabrizi M, Khalili M, Vasei M, Nouraei N, Mansour Samaei N, Khavanin A, Khajehi M, Mowla SJ. **2015**. Evaluating the miR-302b and miR-145 expression in formalin-fixed paraffin-embedded samples of esophageal squamous cell carcinoma. *Arch Iran Med.* 18(3):173–178.
- Tang X, Tian X, Zhang Y, Wu W, Tian J, Rui K, Tong J, Lu L, Xu H, Wang S. **2013**. Correlation between the Frequency of Th17 Cell and the Expression of MicroRNA-206 in Patients with Dermatomyositis. *Clin Dev Immunol.* 2013:345347–345347. doi: [10.1155/2013/345347](https://doi.org/10.1155/2013/345347).
- Tang Y, Xiao G, Chen Y, Deng Y. **2018**. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling. *Anticancer Drugs.* 29(8):725–735. doi: [10.1097/CAD.0000000000000650](https://doi.org/10.1097/CAD.0000000000000650).
- Tang W, Zhu Y, Gao J, Fu J, Liu C, Liu Y, Song C, Zhu S, Leng Y, Wang G, et al. **2014**. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. *Br J Cancer.* 110(2):450–458. doi: [10.1038/bjc.2013.724](https://doi.org/10.1038/bjc.2013.724).
- Tien YT, Chang MH, Chu PY, Lin CS, Liu CH, Liao AT. **2015**. Downregulation of the KLF4 transcription factor inhibits the proliferation and migration of canine mammary tumor cells. *Vet J.* 205(2):244–253. doi: [10.1016/j.tvjl.2014.12.031](https://doi.org/10.1016/j.tvjl.2014.12.031).
- Tsai HC, Tzeng HE, Huang CY, Huang YL, Tsai CH, Wang SW, Wang PC, Chang AC, Fong YC, Tang CH. **2017**. WISP-1 positively regulates angiogenesis by controlling VEGF-A expression in human osteosarcoma. *Cell Death Dis.* 8(4):e2750–e2750. doi: [10.1038/cddis.2016.421](https://doi.org/10.1038/cddis.2016.421).
- Tsang J, Zhu J, van Oudenaarden A. **2007**. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. *Mol Cell.* 26(5):753–767. doi: [10.1016/j.molcel.2007.05.018](https://doi.org/10.1016/j.molcel.2007.05.018).
- Tugal D, Liao X, Jain MK. **2013**. Transcriptional control of macrophage polarization. *Arterioscler Thromb Vasc Biol.* 33(6):1135–1144. doi: [10.1161/ATVBAHA.113.301453](https://doi.org/10.1161/ATVBAHA.113.301453).
- Wang Z, Zhao Q, Li X, Yin Z, Chen S, Wu S, Yang N, Hou Z. **2021**. MYOD1 inhibits avian adipocyte differentiation via miRNA-206/KLF4 axis. *J Anim Sci Biotechnol.* 12(1):55. doi: [10.1186/s40104-021-00579-x](https://doi.org/10.1186/s40104-021-00579-x).
- Weidner J, Bartel S, Kılıç A, Zissler UM, Renz H, Schwarze J, Schmidt-Weber CB, Maes T, Rebane A, Krauss-Etschmann S, et al. **2020**. Spotlight on microRNAs in allergy and asthma. *Allergy.* 76(6):1661–1678. doi: [10.1111/all.14646](https://doi.org/10.1111/all.14646).
- Wisnewski AV, Cooney R, Hodgson M, Giese K, Liu J, Redlich CA. **2022**. Severe asthma and death in a worker using methylene diphenyl diisocyanate MDI asthma death. *Am J Ind Med.* 65(3):166–172. doi: [10.1002/ajim.23323](https://doi.org/10.1002/ajim.23323).
- Wisnewski AV, Liu J, Colangelo CM. **2015**. Glutathione reaction products with a chemical allergen, methylene-diphenyl diisocyanate, stimulate alternative macrophage activation and eosinophilic airway inflammation. *Chem Res Toxicol.* 28(4):729–737. doi: [10.1021/tx5005002](https://doi.org/10.1021/tx5005002).
- Wisnewski AV, Liu J, Redlich CA. **2020**. Analysis of Lung Gene Expression Reveals a Role for Cl(-) Channels in Diisocyanate-induced Airway Eosinophilia in a Mouse Model of Asthma Pathology. *Am J Respir Cell Mol Biol.* 63(1):25–35. doi: [10.1165/rcmb.2019-0400OC](https://doi.org/10.1165/rcmb.2019-0400OC).
- Wong N, Wang X. **2015**. miRDB: an online resource for microRNA target prediction and functional annotations. *Nucleic Acids Res.* 43(Database issue):D146–152. doi: [10.1093/nar/gku1104](https://doi.org/10.1093/nar/gku1104).
- Xia B, Wang L, Feng L, Tian B, Tan Y, Du B. **2018**. Knockdown of Long Noncoding RNA CAT104 Inhibits the Proliferation, Migration, and Invasion of Human Osteosarcoma Cells by Regulating MicroRNA-381. *Oncol Res.* 27(1):89–98. doi: [10.3727/096504018X15199511344806](https://doi.org/10.3727/096504018X15199511344806).
- Xiang Y, Liao X-H, Yao A, Qin H, Fan L-J, Li J-P, Hu P, Li H, Guo W, Li J-Y, et al. **2017**. MRTF-A-miR-206-WDR1 form feedback loop to regulate breast cancer cell migration. *Exp Cell Res.* 359(2):394–404. doi: [10.1016/j.yexcr.2017.08.023](https://doi.org/10.1016/j.yexcr.2017.08.023).
- Xiao H, Li H, Yu G, Xiao W, Hu J, Tang K, Zeng J, He W, Zeng G, Ye Z, et al. **2014**. MicroRNA-10b promotes migration and invasion through KLF4 and HOXD10 in human bladder cancer. *Oncol Rep.* 31(4):1832–1838. doi: [10.3892/or.2014.3048](https://doi.org/10.3892/or.2014.3048).
- Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. **2009**. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. *Cell.* 137(4):647–658. doi: [10.1016/j.cell.2009.02.038](https://doi.org/10.1016/j.cell.2009.02.038).
- Yuan G, Quan J, Dong D, Wang Q. **2018**. Long noncoding RNA CAT104 promotes cell viability, migration, and invasion in gastric carcinoma cells through activation of microRNA-381-inhibiting zinc finger E-box-binding Homeobox 1 (ZEB1) expression. *Oncol Res.* 26(7):1037–1046. doi: [10.3727/096504017X15144748428127](https://doi.org/10.3727/096504017X15144748428127).
- Zhang Y, Fang S, Wang J, Chen S, Xuan R. **2022**. Hsa\_circ\_0008726 regulates the proliferation, migration, and invasion of trophoblast cells in preeclampsia through modulating the miR-1290-LHX6 signaling pathway. *J Clin Lab Anal.* 36(7):e24540.
- Zhang M, Huang S, Long D. **2017**. MiR-381 inhibits migration and invasion in human gastric carcinoma through downregulated SOX4. *Oncol Lett.* 14(3):3760–3766. doi: [10.3892/ol.2017.6637](https://doi.org/10.3892/ol.2017.6637).

- Zhang Q, Pan RR, Wu YT, Wei YM. 2023. MicroRNA-146a promotes embryonic stem cell differentiation towards vascular smooth muscle cells through regulation of Kruppel-like factor 4. *Curr Med Sci.* 43(2):223–231. doi: [10.1007/s11596-023-2736-3](https://doi.org/10.1007/s11596-023-2736-3).
- Zhang PF, Pei X, Li KS, Jin LN, Wang F, Wu J, Zhang XM. 2019. Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells. *Mol Cancer.* 18(1):179. doi: [10.1186/s12943-019-1111-2](https://doi.org/10.1186/s12943-019-1111-2).
- Zhang Q, Wang C, Wu Y, Liu J, Wang T, Wang B. 2023. BAP31-mediated miR-206/133b cluster promotes transendothelial migration and metastasis of colorectal cancer. *Int J Mol Sci.* 24(23):16740. doi: [10.3390/ijms242316740](https://doi.org/10.3390/ijms242316740).
- Zhao L, Zhang X, Shi Y, Teng T. 2020. LncRNA SNHG14 contributes to the progression of NSCLC through miR-206/G6PD pathway. *Thorac Cancer.* 11(5):1202–1210. doi: [10.1111/1759-7714.13374](https://doi.org/10.1111/1759-7714.13374).
- Zheng X, Ma YF, Zhang XR, Li Y, Zhao HH, Han SG. 2020. Circ\_0056618 promoted cell proliferation, migration and angiogenesis through sponging with miR-206 and upregulating CXCR4 and VEGF-A in colorectal cancer. *Eur Rev Med Pharmacol Sci.* 24(8):4190–4202.
- Zhou J, Che J, Xu L, Yang W, Li Y, Zhou W, Zou S. 2022. Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1. *Bioengineered.* 13(3):5737–5755. doi: [10.1080/21655979.2021.2023792](https://doi.org/10.1080/21655979.2021.2023792).